In six healthy subjects, glucagon reduced mean superior mesenteric artery blood flow by 31.8%, with a range of 20 to 56%. P < 0.05.
In plain wordsIn healthy subjects, glucagon reduced intestinal artery blood flow from baseline.
- Peptide
- Glucagon
- Outcome
- DecreaseSuperior mesenteric artery blood flow
- Study
n = 6
- Comparator
- Baseline
- Outcome group
- Vascular function · Cardiovascular
- Studied dose
- 3 ng min-1kg-1As given in this study (human).
Measurements
- Mean superior mesenteric artery blood flow change
- −31.8 % of baseline
- glucagon 3 ng min-1kg-1
- Range of superior mesenteric artery blood flow change
- −56 to −20 % of baseline
- glucagon 3 ng min-1kg-1
Source sentences
Mean superior mesenteric artery blood flow fell during the 3 and 6 ng min-1kg-1 glucagon infusions (3 ng min-1kg-1: -31.8%, range -20 to -56% of baseline; 6 ng min-1kg-1: -20.7%, range -8 to -53% of baseline; P < 0.05).
1 context sentence(design, population, supporting numbers)
In study 1, superior mesenteric artery blood flow was measured by Doppler ultrasound in six normal subjects during either saline or glucagon infusion at 1, 3 and 6 ng min-1kg-1, which resulted in circulating glucagon levels within the physiological range.